Table 5 Comparison of demographics, comorbid conditions, and clinical characteristics across vancomycin treatment

Vancomycin dose (mg/kg/d)^a

55.2 ± 4.4

72 ± 8.9

 < 0.001

No. of patients in different age groups^b

 Group –I

14 (15.7)

31 (22.3)

 < 0.001

 Group –II

31 (34.8)

39 (28.1)

0.027

 Group -III

10 (11.2)

45 (32.3)

 < 0.001

 Group -IV

34 (38.2)

24 (17.2)

0.045

Concomitant inotropic support^a

 Yes

24 (21.4)

49 (35.3)

0.045

Concomitant nephrotoxic drug^a,e

 1 Medicine

56 (62.9)

110 (79.2)

0.008

 2 Medicines

43 (48.3)

78 (56.2)

0.007

 3 Medicines

8 (8.9)

22 (15.8)

0.016

 4 or more Medicines

4 (4.5)

11 (7.9)

0.045

Culture proven infection^a

 Yes

51 (57.3)

99 (71.2)

0.003

Identified Pathogen^a

 Coagulase-negative Staphylococcus spp.

16 (17.9)

22 (15.8)

0.087

 MRSA

12 (13.5)

21 (15.1)

0.077

 Enterococcus spp.

7 (7.8)

19 (13.7)

0.045

 Streptococci pneumoniae

8 (8.9)

11 (7.9)

0.091

 Others^d

8 (8.9)

26 (18.7)

0.004

Baseline serum creatinine (mg/dL)^a

0.55 ± 0.21

0.54 ± 0.23

0.067

Duration of therapy (days)^c

Culture proven

 Median (range) Mean (SD)

20 (11–35) 18.4 ± 12.2

18 (9–26) 15.1 ± 8.9

0.025

Clinical sepsis

 Median (range) Mean (SD)

6 (3–9) 5.8 ± 4.4

7 (5–7) 5.7 ± 3.2

0.071

Outcome of therapy

 Developed nephrotoxicity^b

11 (9.9)

14 (10.1)

0.086

 Developed Electrolyte imbalance^b

16 (17.9)

22 (15.8)

0.078

 Length of hospital stay^c

22 (8–55)

16 (8–37)

0.011

 Survival^b

75 (84.3)

129 (92.8)

0.008